Browsing Tag
generic drugs
13 posts
Glenmark Pharmaceuticals (NSE: GLENMARK) launches GLIPIQ semaglutide in India at Rs 325 a week as generic GLP-1 era starts
Glenmark Pharmaceuticals launches GLIPIQ semaglutide in India from Rs 325 a week. Analysis of pricing, competition, and what it means for GLP-1 access. Read more.
Strait of Hormuz standoff raises risks to global supply of antibiotics, diabetes drugs, and blood pressure medicines
Strait of Hormuz closure disrupts petrochemical feedstocks and logistics for India's generic drug sector, raising US prescription supply and pricing risks.
Tentative approval granted to Alembic Pharmaceuticals for pulmonary hypertension treatment by FDA
Alembic Pharmaceuticals Limited has achieved a significant milestone by securing tentative approval from the US Food & Drug…
Can Lupin’s clean FDA inspection at its Vizag API plant boost confidence in its global supply reliability?
Lupin’s Vizag API plant clears US FDA inspection with no observations, strengthening its US supply reliability and regulatory track record.
Is this Lupin’s next U.S. respiratory blockbuster? Generic Perforomist hits the shelves
Lupin launches generic Perforomist in the U.S. for asthma and COPD, eyeing a $268M market. Find out how this move boosts its global respiratory portfolio.
Lupin Limited secures US FDA tentative approval for generic version of rosacea drug Oracea
Lupin Limited gains US FDA tentative approval for generic Oracea, targeting the $215M rosacea drug market in the US.
Alembic Pharmaceuticals secures US FDA approval for Ketorolac Tromethamine injectable as generic to Roche’s Toradol
Alembic Pharmaceuticals wins US FDA approval for Ketorolac Tromethamine injectable, a generic to Roche’s Toradol, expanding its US sterile injectables portfolio.
Can Aurobindo Pharma’s FDA EIR for its Telangana oral manufacturing facility boost US generics supply confidence?
Aurobindo Pharma secures a US FDA EIR with VAI status for its Telangana oral manufacturing facility, ensuring uninterrupted US generics supply.
Marksans Pharma secures US FDA approval for multiple strengths of Pregabalin capsules in key neuropathic pain segment
Marksans Pharma wins US FDA approval for multi-strength Pregabalin capsules, targeting a USD 263M neuropathic pain market in the United States.
Lupin secures FDA approval for generic Truvada, expanding HIV treatment and prevention portfolio in the US
Lupin secures US FDA approval for its generic version of Truvada, targeting HIV treatment and prevention. See what this means for the $2.1B US market.